Naloxegol for treating opioid‑induced constipation

  • Technology appraisal guidance
  • TA345
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Kleijnen Systematic Reviews Ltd:

  • Wolff R, Al M, Zaim R, Lang S, Leunis A, Noake C, Ryder S, Worthy G, Stirk L, Armstrong N, Riemsma R, Severens JL, Kleijnen J. Naloxegol for treating opioid‑induced constipation: a Single Technology Appraisal. York: Kleijnen Systematic Reviews Ltd, 2015

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • AstraZeneca

II. Professional/expert and patient/carer groups:

  • PromoCon

  • The IBS Network

  • Association of Cancer Physicians

  • Association of Coloproctology of Great Britain and Ireland

  • Cancer Research UK

  • Royal College of Physicians

III. Other consultees:

  • Department of Health

  • NHS England

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Boehringer Ingelheim (bisacodyl, docusate, macrogol, sodium picosulphate)

  • Napp Pharmaceuticals Limited (naloxone‑oxycodone)

  • Norgine Pharmaceuticals (sterculia/ frangula, macrogol, docusate sodium enema)

  • TMC Pharma Services (methylnaltrexone bromide)

  • National Cancer Research Institute

  • Kleijnen Systematic Reviews

  • National Institute for Health Research Health Technology Assessment Programme

  • National Collaborating Centre for Cancer

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on naloxegol for treating opioid‑induced constipation by attending the initial Committee discussion and providing a written statement to the Committee. They are invited to comment on the ACD.

  • Dr Andrew Davies, Clinical Director Supportive & Palliative Care, nominated by AstraZeneca – clinical expert

  • Dr Paul Farquhar‑Smith, Consultant in Anaesthesia and Pain Management, nominated by AstraZeneca – clinical expert

  • Karen Irwin, Services Manager / Specialist Nurse, nominated by Promocon – patient expert

E. Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • AstraZeneca